Pan-Biome reports positive results in gut microbiome modulator trial

Lead compound exhibits protective effects in inflammatory colitis, modulates gut microbiome and extends lifespan in C elegans.

Pan-Biome Pharmaceuticals, a Vancouver based preclinical biopharmaceutical company focused on age-related diseases and extending human healthspan, has announced today that its lead compound exhibited protective effects in a preclinical model of inflammatory colitis.

My take on this: While colitis doesn’t usually have a direct impact on life expectancy, colitis-associated comorbidity does, and colitis can also contribute to bone loss and joint inflammation and increase the risk of blood clots and colon cancer. Moreover, there is a significant link between colitis and the gut microbiome, which plays a crucial role in maintaining a healthy immune system and preventing disease. Dysbiosis of the gut microbiome in people with colitis can lead to inflammation and damage to the intestinal lining, exacerbating symptoms and increasing the risk of associated comorbidities.

The health of the gut microbiome is closely linked to overall healthspan; an unhealthy gut microbiome has been linked to an increased risk of chronic diseases, including obesity, diabetes, cardiovascular disease and cancer, whereas in contrast, a healthy gut microbiome can help maintain a healthy weight, improve nutrient absorption and reduce inflammation, all of which can contribute to a longer and healthier life. Being able to modulate the gut microbiome will help to foster far more positive outcomes.

Dr Andy Sham, PhD, Pan-Biome Scientific Advisor and project manager for the Gut4Health Microbiome Core at BC Children’s Hospital Research Institute said: “Our team has conducted extensive testing of this compound through numerous in vitro and in vivo studies. We have found that the compound demonstrates selective antimicrobial activity and has the ability to modulate the gut microbiome in mice.

“In our most recent study, we observed that the lead compound is well-tolerated when administered orally and provides protective effects in a dextran sulfate sodium-induced mouse model of colitis.”

Recent studies show clear differences between the gut microbiome composition in healthy people versus those with Parkinson’s and Alzheimer’s disease, with altered gut microbiota contributing to inflammation in the body that may spread to the brain.

Learn more insights straight from Pan-Biome CSO Dr Poul Sorensen and CEO Gordon Eberwein, HERE.

Thanks for reading! If you’ve enjoyed this article, it would mean a lot to me if you could subscribe and share it on LinkedIn!